<p>Victrex（伦敦证券交易所代码：VCT - 获取免费报告）在周一发布了季度财报。该公司报告季度每股收益为 17.20 便士，Digital Look Earnings 报道。Victrex 的股本回报率为 6.40%，净利润率为 9.50%。该公司季度收入为 1.471 亿英镑。</p>
<p>以下是 Victrex 电话会议的主要要点：</p>
<ul>
<li><strong>Victrex 上半年的收入增长了 1%</strong>，达到 1.471 亿英镑，得益于强劲的第二季度和 6% 的销量增长，但定价和产品组合抵消了一部分收益。</li>
<li><strong>盈利能力减弱</strong>，基础税前利润下降 18%，至 1900 万英镑，毛利率从 44.1% 降至 41.7%，主要由于价格压力、产品组合、货币因素和医疗销售疲软。</li>
<li><strong>现金生成保持稳健</strong>，自由现金流为 2200 万英镑，现金转换率为 109%，净债务为可控的 0.65 倍 EBITDA。</li>
<li>公司在中国制造工厂记录了 <strong>6060 万英镑的非现金减值</strong>，因为发现一个生产步骤限制了原定 1500 吨的产能。管理层强调这是一个运营问题，而非需求问题，中国的需求依然强劲。</li>
<li><strong>管理层正在采取积极的重组措施</strong>，包括全球员工减少 10%、新的分散运营模式和产品组合简化，并计划在 9 月举行资本市场日以详细说明战略和中期盈利改善计划。</li>
</ul>
<h2>Victrex 价格表现</h2>
<p>LON VCT 的股票周一开盘价为 581 便士。该公司的市值为 5.0619 亿英镑，市盈率为 18.27，市盈增长比率为 1.92，贝塔值为 0.75。Victrex 的 52 周低点为 515 便士，52 周高点为 882 便士。该公司的债务与股本比率为 11.30，速动比率为 1.99，流动比率为 3.01。该股票的 50 日移动平均线为 612.46 便士，200 日移动平均线为 644.88 便士。</p>
<h2>华尔街分析师预测增长</h2>
<p>VCT 已成为几份研究报告的主题。摩根大通将 Victrex 的目标价从 725 便士下调至 625 便士，并在 3 月 18 日的研究报告中对该股票给予 “买入” 评级。Canaccord Genuity Group 在 4 月 13 日的研究报告中重申了 “买入” 评级，并对 Victrex 的股票设定了 725 便士的目标价。两位股票研究分析师对该股票给予 “买入” 评级，三位分析师则给予 “持有” 评级。根据 MarketBeat 的数据，Victrex 的平均评级为 “持有”，共识目标价为 750 便士。</p>
<p><strong>查看我们最新的 VCT 股票分析</strong></p>
<h2>关于 Victrex</h2>
<p>（获取免费报告）</p>
<p>Victrex plc 通过其子公司在全球范围内从事聚合物解决方案的制造和销售。该公司通过可持续解决方案和医疗两个部门运营。它开发 PEEK 和 PAEK 基聚合物解决方案，以及半成品和成品。该公司还为医疗设备制造商提供专业解决方案；销售热塑性聚合物；为能源和工业、VAR、汽车、航空航天和电子市场提供可持续解决方案；并从事贸易活动。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Victrex</li>
<li>超越 NVIDIA：强劲势头的 AI 相关股票</li>
<li>量子财报季正在加速——关注两大主要参与者</li>
<li>Flutter 在财报后看到提振，FanDuel 显示复苏迹象</li>
<li>3 只医疗保健股票将受益于这项重大法案</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PUxPTiZTeW1ib2w9VkNU?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PUxPTiZTeW1ib2w9VkNU"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Victrex 吗？</h2>
<p>在考虑 Victrex 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Victrex 并不在名单上。</p>
<p>虽然 Victrex 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Victrex（伦敦证券交易所代码：VCT）报告了本季度每股收益为 17.20 便士，收入为 1.471 亿英镑。该公司在上半年经历了 1% 的收入增长，但盈利能力下降，税前基础利润下降 18%，至 1900 万英镑。其中国工厂记录了 6060 万英镑的非现金减值。管理层正在实施重组措施，包括全球员工人数减少 10%。分析师的评级意见不一，普遍目标价为 750 便士，目前评级为 “持有”</p>

<p>Victrex (LON:VCT - Get Free Report) posted its quarterly earnings data on Monday. The company reported GBX 17.20 EPS for the quarter, Digital Look Earnings reports. Victrex had a return on equity of 6.40% and a net margin of 9.50%.The firm had revenue of £147.10 million for the quarter.</p>
<div class="lb-trans"><p>Victrex（伦敦证券交易所代码：VCT - 获取免费报告）在周一发布了季度财报。该公司报告季度每股收益为 17.20 便士，Digital Look Earnings 报道。Victrex 的股本回报率为 6.40%，净利润率为 9.50%。该公司季度收入为 1.471 亿英镑。</p>
</div><p>Here are the key takeaways from Victrex's conference call:</p>
<div class="lb-trans"><p>以下是 Victrex 电话会议的主要要点：</p>
</div><ul>
<li><strong>Victrex’s H1 revenue rose 1%</strong> to GBP 147.1 million, helped by a strong Q2 and 6% volume growth, but pricing and mix offset some of the benefit.</li>
<li><strong>Profitability weakened</strong>, with underlying PBT down 18% to GBP 19 million and gross margin falling to 41.7% from 44.1% due to price pressure, mix, currency, and softer medical sales.</li>
<li><strong>Cash generation remained solid</strong>, with free cash flow of GBP 22 million, cash conversion of 109%, and net debt at a manageable 0.65x EBITDA.</li>
<li>The company recorded a <strong>GBP 60.6 million non-cash impairment</strong> on its China manufacturing plant after concluding one production step is limiting capacity versus the original 1,500-ton nameplate. Management emphasized this is an operational issue, not a demand issue, and China demand remains strong.</li>
<li><strong>Management is taking aggressive restructuring actions</strong>, including a 10% global headcount reduction, a new decentralized operating model, and portfolio simplification, with a September capital markets day planned to detail the strategy and medium-term profit improvement plan.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Victrex 上半年的收入增长了 1%</strong>，达到 1.471 亿英镑，得益于强劲的第二季度和 6% 的销量增长，但定价和产品组合抵消了一部分收益。</li>
<li><strong>盈利能力减弱</strong>，基础税前利润下降 18%，至 1900 万英镑，毛利率从 44.1% 降至 41.7%，主要由于价格压力、产品组合、货币因素和医疗销售疲软。</li>
<li><strong>现金生成保持稳健</strong>，自由现金流为 2200 万英镑，现金转换率为 109%，净债务为可控的 0.65 倍 EBITDA。</li>
<li>公司在中国制造工厂记录了 <strong>6060 万英镑的非现金减值</strong>，因为发现一个生产步骤限制了原定 1500 吨的产能。管理层强调这是一个运营问题，而非需求问题，中国的需求依然强劲。</li>
<li><strong>管理层正在采取积极的重组措施</strong>，包括全球员工减少 10%、新的分散运营模式和产品组合简化，并计划在 9 月举行资本市场日以详细说明战略和中期盈利改善计划。</li>
</ul>
</div><h2>Victrex Price Performance</h2>
<div class="lb-trans"><h2>Victrex 价格表现</h2>
</div><p>Shares of LON VCT opened at GBX 581 on Monday. The stock has a market cap of £506.19 million, a PE ratio of 18.27, a price-to-earnings-growth ratio of 1.92 and a beta of 0.75. Victrex has a fifty-two week low of GBX 515 and a fifty-two week high of GBX 882. The company has a debt-to-equity ratio of 11.30, a quick ratio of 1.99 and a current ratio of 3.01. The stock has a fifty day moving average of GBX 612.46 and a 200-day moving average of GBX 644.88.</p>
<div class="lb-trans"><p>LON VCT 的股票周一开盘价为 581 便士。该公司的市值为 5.0619 亿英镑，市盈率为 18.27，市盈增长比率为 1.92，贝塔值为 0.75。Victrex 的 52 周低点为 515 便士，52 周高点为 882 便士。该公司的债务与股本比率为 11.30，速动比率为 1.99，流动比率为 3.01。该股票的 50 日移动平均线为 612.46 便士，200 日移动平均线为 644.88 便士。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>VCT has been the topic of several research reports. JPMorgan Chase &amp; Co. lowered their target price on Victrex from GBX 725 to GBX 625 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, March 18th. Canaccord Genuity Group reiterated a &#34;buy&#34; rating and issued a GBX 725 price target on shares of Victrex in a research report on Monday, April 13th. Two equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, Victrex has an average rating of &#34;Hold&#34; and a consensus price target of GBX 750.</p>
<div class="lb-trans"><p>VCT 已成为几份研究报告的主题。摩根大通将 Victrex 的目标价从 725 便士下调至 625 便士，并在 3 月 18 日的研究报告中对该股票给予 “买入” 评级。Canaccord Genuity Group 在 4 月 13 日的研究报告中重申了 “买入” 评级，并对 Victrex 的股票设定了 725 便士的目标价。两位股票研究分析师对该股票给予 “买入” 评级，三位分析师则给予 “持有” 评级。根据 MarketBeat 的数据，Victrex 的平均评级为 “持有”，共识目标价为 750 便士。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on VCT</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 VCT 股票分析</strong></p>
</div><h2>About Victrex</h2>
<div class="lb-trans"><h2>关于 Victrex</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Victrex plc, through its subsidiaries, engages in the manufacture and sale of polymer solutions worldwide. The company operates through two segments, Sustainable Solutions and Medical. It develops PEEK and PAEK based polymer solutions, and semi-finished and finished parts. The company also provides specialist solutions for medical device manufacturers; sells thermoplastic polymers; sustainable solutions for energy and industrial, VAR, automotive, aerospace, and electronics markets; and engages in trading activities.</p>
<div class="lb-trans"><p>Victrex plc 通过其子公司在全球范围内从事聚合物解决方案的制造和销售。该公司通过可持续解决方案和医疗两个部门运营。它开发 PEEK 和 PAEK 基聚合物解决方案，以及半成品和成品。该公司还为医疗设备制造商提供专业解决方案；销售热塑性聚合物；为能源和工业、VAR、汽车、航空航天和电子市场提供可持续解决方案；并从事贸易活动。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Victrex</li>
<li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li>
<li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li>
<li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Victrex</li>
<li>超越 NVIDIA：强劲势头的 AI 相关股票</li>
<li>量子财报季正在加速——关注两大主要参与者</li>
<li>Flutter 在财报后看到提振，FanDuel 显示复苏迹象</li>
<li>3 只医疗保健股票将受益于这项重大法案</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PUxPTiZTeW1ib2w9VkNU" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=LON&amp;Symbol=VCT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Victrex Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Victrex 吗？</h2>
</div><p>Before you consider Victrex, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Victrex 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Victrex wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Victrex 并不在名单上。</p>
</div><p>While Victrex currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Victrex 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Victrex（伦敦证券交易所代码：VCT）公布了收益结果